Join Raajit Rampal, MD, PhD, as he provides expert insight on key trials from ASH 2023 that explore new treatment options for myeloproliferative neoplasms.
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/ash-2023-mpns/18453-27394
- Start Date: 2024-03-06 06:00:00
- End Date: 2024-03-06 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AbbVie (Any division) - Amount: 0.0 - Is Kind Support: False Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 0.0 - Is Kind Support: False Source: Regeneron Pharmaceuticals, Inc. - Amount: 0.0 - Is Kind Support: False Source: Seagen - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest